Brück et al., 2013 - Google Patents
Therapeutic decisions in multiple sclerosis: moving beyond efficacyBrück et al., 2013
View HTML- Document ID
- 13035256558490635356
- Author
- Brück W
- Gold R
- Lund B
- Oreja-Guevara C
- Prat A
- Spencer C
- Steinman L
- Tintoré M
- Vollmer T
- Weber M
- Weiner L
- Ziemssen T
- Zamvil S
- Publication year
- Publication venue
- JAMA neurology
External Links
Snippet
Several innovative disease-modifying treatments (DMTs) for relapsing-remitting multiple sclerosis have been licensed recently or are in late-stage development. The molecular targets of several of these DMTs are well defined. All affect at least 1 of 4 properties, namely …
- 201000006417 multiple sclerosis 0 title description 136
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brück et al. | Therapeutic decisions in multiple sclerosis: moving beyond efficacy | |
| Howard et al. | Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial | |
| Bronckers et al. | Safety of systemic agents for the treatment of pediatric psoriasis | |
| Baker et al. | Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab | |
| Kim et al. | Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica | |
| Vargas et al. | Update on disease-modifying therapies for multiple sclerosis | |
| Hatcher et al. | Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment | |
| Jabbour et al. | Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory Philadelphia chromosome–negative acute lymphoblastic leukemia: a phase 2 clinical trial | |
| Ringelstein et al. | Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder | |
| Yeh et al. | Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis | |
| Wald et al. | Effect of pritelivir compared with valacyclovir on genital HSV-2 shedding in patients with frequent recurrences: a randomized clinical trial | |
| Long et al. | Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials | |
| Naegelin et al. | Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis | |
| Kao et al. | Neurological complications associated with anti–programmed death 1 (PD-1) antibodies | |
| Weinstock-Guttman et al. | Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease) | |
| Minagar et al. | Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial | |
| Boyce et al. | Sarilumab: review of a second IL-6 receptor antagonist indicated for the treatment of rheumatoid arthritis | |
| Mealy et al. | Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy | |
| Finkelsztejn | Multiple sclerosis: overview of disease-modifying agents | |
| Tourbah et al. | MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study | |
| Rudick et al. | Natalizumab: bench to bedside and beyond | |
| Leonardi et al. | Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial | |
| Rudick | Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics | |
| Torkildsen et al. | ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial | |
| Cohen et al. | Equivalence of generic glatiramer acetate in multiple sclerosis: a randomized clinical trial |